Global landscape of CAR cell therapeutic companies

by Alexey Bersenev on February 2, 2018 · 0 comments

in market

Using recently released Cellular Immunotherapy Companies dataset, I attempted to quantify all therapeutic CAR cell companies worldwide. The dataset includes companies with therapeutic assets/ programs in different stages of development, but not manufacturers of reagents/ devices or service providers.

I was able to identify 115 of CAR cell therapeutic companies. It is ~53% of all immunocellular therapy companies. The vast majority of companies are startups with wholly owned CAR cell assets/ programs. At least 14 large BioPharma companies currently have CAR cell programs/ assets, obtained via licensing and/ or acquisitions (e.g. Pfizer, Amgen, Shire, Regeneron, Johnson & Johnson, ONO Pharmaceuticals, Takeda…). 17 companies (15%), besides CAR cell programs, have other immunocellular product-candidates in development (e.g. NK cells, TCR-T, DC…). About 1/3 of all CAR cell therapeutic companies are in a very early phase of development (preclinical) and 2/3 are conducting clinical trials. Only 2 companies have approved CAR cell products on a market.

Here is a global geographical distribution of CAR cell therapeutic companies (click to enlarge):

CAR tx companies global

Overall, 15 countries have CAR cell companies with a therapeutic focus. China takes 42% of global share of all companies, US – 33%.

Almost all of these companies appeared in the last 5 years (since 2012). Despite some trends for consolidation through acquisition by larger companies (e.g. Gilead –> Kite Pharma, Celgene –> Juno Therapeutics), a number of CAR cell stratups continues to explode. I wanted to illustrate here that CAR cell industry explosion is becoming global and it is spreading rapidly.

{ 0 comments… add one now }

Leave a Comment

Previous post: